Literature DB >> 3876368

Evidence that lymphokine-activated killer cells and natural killer cells are distinct based on an analysis of congenitally immunodeficient mice.

G L Andriole, J J Mulé, C T Hansen, W M Linehan, S A Rosenberg.   

Abstract

The in vitro incubation of lymphoid cells in RIL 2 results in the generation of LAK cells that are broadly lytic to autologous, syngeneic, and allogeneic fresh tumor cells, but which do not lyse fresh, normal cells. Strains of mice with congenital immunodeficiencies were tested both for the presence of NK cells and for their capacity to generate LAK cells after in vitro incubation with IL 2. Splenocytes obtained from two immunodeficient mouse strains (NIH-Beige-Nude and NIH-Beige-Nude-XID) failed to generate LAK cells, but displayed significant activity. Splenocytes from another immunodeficient mouse strain (NIH-Beige-XID) generated LAK cells but did not display NK cell activity. This dissociation of activation of LAK cells from NK cells among the immunodeficient strains indicates that the LAK and NK cell lytic systems are distinct.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3876368

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

1.  Peripheral blood lymphocytes from thermal injury patients are defective in their ability to generate lymphokine-activated killer (LAK) cell activity.

Authors:  G R Klimpel; D H Herndon; M D Stein
Journal:  J Clin Immunol       Date:  1988-01       Impact factor: 8.317

Review 2.  Experimental oral candidiasis in animal models.

Authors:  Y H Samaranayake; L P Samaranayake
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

3.  Induction of activated natural killer cells from murine spleen cells primed in vivo and subsequently challenged in vitro with the streptococcal preparation OK432.

Authors:  H Yamaue; M Katsumi; K Tabuse; Y Tabuse; K Kuribayashi; T Nishihara; K Saito
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

4.  Regulation by recombinant interleukin-2 of protective immunity against recurrent herpes simplex virus type 2 genital infection in guinea pigs.

Authors:  A Weinberg; M Konrad; T C Merigan
Journal:  J Virol       Date:  1987-07       Impact factor: 5.103

5.  The NIH-3 immunodeficient mouse is a model for Lyme borreliosis myositis and carditis.

Authors:  D L Defosse; P H Duray; R C Johnson
Journal:  Am J Pathol       Date:  1992-07       Impact factor: 4.307

6.  Long-term cytokine production from engineered primary human stromal cells influences human hematopoiesis in an in vivo xenograft model.

Authors:  M A Dao; K A Pepper; J A Nolta
Journal:  Stem Cells       Date:  1997       Impact factor: 6.277

7.  Activation of swine peripheral blood lymphocytes with human recombinant interleukin-2.

Authors:  R C Bhagyam; D Jarrett-Zaczek; F G Ferguson
Journal:  Immunology       Date:  1988-08       Impact factor: 7.397

8.  Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma.

Authors:  H Hock; M Dorsch; U Kunzendorf; Z Qin; T Diamantstein; T Blankenstein
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

9.  Immunity to melanoma in mice immunized with transfected allogeneic mouse fibroblasts expressing melanoma-associated antigens.

Authors:  Y S Kim; R Slomski; E P Cohen
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

10.  Antiviral effect of lymphokine-activated killer cells: characterization of effector cells mediating prophylaxis.

Authors:  J F Bukowski; H Yang; R M Welsh
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.